68 results about "Organ dysfunction" patented technology

Methods for the treatment of acute renal failure, multi-organ failure, early dysfunction of kidney transplant, chronic renal failure, organ dysfunction, and wound healing are provided. The methods include delivering a therapeutic amount of hematopoietic stem cells, non-hematopoietic, mesenchymal stem cells, hemangioblasts, and pre-differentiated cells to a patient in need thereof.

The invention discloses a multiple organ function support system, formed by a body, an external blood circuit, a plasma separating-adsorbing circuit, an albumin circuit, a dialysate circuit, a feeding circuit and an operating system. The invention can eliminate the inflammation medium, toxin and lots of middle and small molecule materials in the body of multiple organ function obstacle complex symptom (MODS) patient, and uses a lung membrane oxygen generator to replace the air exchange function of lung, to be used in reversal breath exhaustion, and uses albumin circulate purification treatment to completely eliminate the protein combine toxin and soluble small molecule toxin (as blood ammonia) of lung exhaustion patient, and accurately release water slowly. The invention can combine the support functions of lung, heart, kidney and liver, based on present clinic test and technique, with wide application.

A method of retarding cellular senescence comprising (i) providing an extracellular matrix (ECM) composition comprising ECM from an adolescent tissue source, the ECM comprising an exogenously added cytokine, and (ii) administering ECM composition to an organ with cells exhibiting cellular senescence, wherein, the cytokine interacts with at least one molecule in the ECM composition and modulates ROS production of the cells, whereby, the cellular senescence is abated.

The present invention is related to the use of secretagogue peptides repeatedly administered as part of a pharmaceutical composition that prevent and eradicate the deposition of pathological fibrotic material in parenchymal tissues of internal organs like the liver, lungs, esophagus, small intestine, kidneys, blood vessels, joints, and other systemic forms of cutaneous fibrosis of any etiopathogenesis. Additionally, these peptides prevent and eradicate deposition of amiloid and hyaline materials in any of their correspondent chemical forms and tissue manifestations in the brain, cerebellum, blood vessels, liver, intestines, kidneys, spleen, pancreas, joints and the skin, among others. By this way, cellular, tissular and organ dysfunctions generated by these depositions are corrected. The peptides of the present invention are infiltrated or topically applied, contributing to prevent and eradicate keloids and hypertrophic scars in the skin, derived as sequelae of burns and other cutaneous trauma.

The present invention relates to a solution for preservation, perfusion, and / or reperfusion of an organ, especially the heart, for transplantation. The solution contains peptide inhibitor(s) of protein kinase C βII (PKC βII) and / or of protein kinase C ζ (PKC ζ) and / or peptide activator(s) of protein kinase C δ (PKCδ). Methods for using the inventive solution are also disclosed, including methods for preserving an organ for transplantation, for protecting an ischemic organ from damage, for attenuating organ dysfunction after ischemia, for maintaining nitric oxide release and / or inhibiting superoxide release in an ischemic organ, and for protecting an organ from damage when isolated from the circulatory system.

The present invention provides an agent for preventing or treating organ functional disorders, an agent for preventing or treating organ dysfunction and an agent for preventing or treating obesity and deuteropathy thereof, each of which comprises a compound having an effect of increasing ubiquinone or a salt thereof or a prodrug thereof; as well as a ubiquinone increasing agent comprising a compound having a squalene synthase inhibitory effect or a salt thereof or a prodrug thereof.

Compositions and methods are disclosed for decreasing the amount and activity of matrix-degrading metalloproteinases (MMPs) in and around cells. The compositions and methods are useful for treating and / or preventing symptoms of diseases including but not limited to Hypertension, Type II Diabetes, and Metabolic Syndrome X. Such treatment is effected by normalizing the blood plasma's protease activity, reducing blood pressure, preventing membrane receptor cleavage, and reducing the levels of insulin resistance and oxygen free radicals in the blood stream.

The present invention is related to the use of secretagogue peptides repeatedly administered as part of a pharmaceutical composition that prevent and eradicate the deposition of pathological fibrotic material in parenchymal tissues of internal organs like the liver, lungs, esophagus, small intestine, kidneys, blood vessels, joints, and other systemic forms of cutaneous fibrosis of any etiopathogenesis. Additionally, these peptides prevent and eradicate deposition of amiloid and hyaline materials in any of their correspondent chemical forms and tissue manifestations in the brain, cerebellum, blood vessels, liver, intestines, kidneys, spleen, pancreas, joints and the skin, among others. By this way, cellular, tissular and organ dysfunctions generated by these depositions are corrected. The peptides of the present invention are infiltrated or topically applied, contributing to prevent and eradicate keloids and hypertrophic scars in the skin, derived as sequelae of burns and other cutaneous trauma.

Methods and a composition for the treatment of organ dysfunction, acute renal failure, multi-organ failure, early dysfunction of kidney transplant, graft rejection, chronic renal failure, wounds, and inflammatory disorders including media conditioned by mesenchymal stem cells are provided. Methods for modulation of growth factor and cytokine expression including administering a therapeutic amount of mesenchymal stem cells, endothelial cells derived from mesenchymal stem cells, or media conditioned by mesenchymal stem cells are also provided.

The present invention provides an agent for the prophylaxis or treatment of severe sepsis, which contains a compound represented by the formula (I): or, the formula (II): , or a salt thereof or a prodrug thereof, a TLR signal inhibitor containing a non-peptide compound and an agent for the prophylaxis or treatment of organ dysfunction and the like, which contains a TLR signal inhibitory substance.

This invention is directed to a pharmaceutical composition comprising the sodium-hydrogen exchanger (NHE) inhibitor cariporide and an angiotensin converting enzyme (ACE) inhibitor which exhibits unexpectedly efficacious properties for preventing heart failure and other age-related organ dysfunctions, age-related disorders and for prolonging life, and to methods of preventing heart failure and other age-related organ dysfunctions, age-related disorders and for prolonging life comprising administering pharmaceutically effective amounts of the sodium-hydrogen exchange inhibitor cariporide and an ACE inhibitor.

An oligonucleotide with a nucleotide sequence of 5′-cctcctcctcctcctcctcctcct-3′ (SEQ ID NO: 1) inhibits proliferation of human PBMC activated by TLR9 agonist and interferon production from human PBMC induced by TLR9 agonist, HSV-1, flu virus and serum from SLE patients, and rescues the mice from cytokine-mediated lethal shock. This oligonucleotide can be used as a remedy for the treatment of systemic lupus erythematosus (SLE), sepsis, multiple organ dysfunction syndromes and other immune-mediated disorders.

The invention discloses a magnetic device applicable to anastomosis of large vessels. Two elliptic-cylinder-shaped anastomosing rings which correspond to the pipe diameter of the large vessels to be anastomosed and contain permanent magnets are utilized to finish anastomosis of the vessels with different pipe diameters; the opposite surfaces of two permanent magnet anastomosing rings are smooth and polished, so that the endangiums of the vessels are neatly aligned, and further the defects of narrow anastomosing ports, blood leakage, and various complications such as massive haemorrhage, local tissue granuloma and pseudoartery formation and the like due to slipping of ligatures caused by manual suture for anastomosis are avoided; as the anastomosing rings are designed to be elliptic-cylinder-shaped, clamping and fixing with surgical instruments in surgery are convenient, and the magnetic device is very beneficial to anastomosis operation of the large vessels at deep parts of the body cavity; and the time of utilizing the anastomat to carry out anastomosis on the large vessels is more than five times shorter than that of manual anastomosis, so that the condition that the blood of tissues and organs are blocked for long time so as to cause ischemic operation of the organs or congestion and edema and further cause dysfunction of the organs. In addition, the end surface adopts conical titanium alloy needles and corresponding conical small holes so as to be beneficial to tight alignment of the anastomosing ports in surgery.

The invention relates to a human high density lipoprotein and product, preparation process and use thereof, which comprises producing human plasma albumin and gamma globulin by employing low-temperature ethanol method, using discarded FIV-1 deposition as raw material, extracting HDL from FIV-1 through separation and purification steps. The prepared human high density lipoprotein and product can be applied for the preparation of medicament for treating multiple organ disturbance syndrome (MODS) and cardiovascular diseases such as atherosclerosis (AS).

Methods of preventing and / or treating ischemia, organ dysfunction and / or organ failure, including multiple organ dysfunction syndrome (MODS), and necrosis and apoptosis associated with organ dysfunction / failure, are provided. For instance, the methods involve contacting organ(s) with an oxygenated cholesterol sulfate (OCS), e.g. 5-cholesten-3,25-diol, 3-sulfate (25HC3S). The organ(s) may be in vivo (e.g. in a patient that is treated with the OCS) or ex vivo (e.g. an organ that has been harvested from a donor and is to be transplanted).

The embodiments of the invention relate to the field of immunoassay, and in particular to a human heparin binding protein assay kit with high sensitivity and wide detection range. The human heparin binding protein assay kit comprises: a reagent 1, a reagent 2 and human HBP calibrators with different concentration gradients. The reagent 2 comprises a carboxyl latex microsphere labeled only with human HBP monoclonal antibody and a carboxyl latex microsphere labeled only with human HBP polyclonal antibody. The average particle diameter of the carboxyl latex microsphere labeled only with the humanHBP monoclonal antibody > the average particle diameter of the carboxyl latex microsphere labeled only with the human HBP polyclonal antibody. The human heparin binding protein assay kit provided bythe invention can complete a single sample test within 10 minutes, and indexes of precision, accuracy and anti-interference are excellent. The invention can be used clinically to predict an organ dysfunction caused by sepsis, and can be used as an early diagnostic marker for sepsis, especially serious bacterial infection.

The invention provides a method for sepsis diagnosis, severity degree monitoring, and prognosis evaluation. The enzymatic activity level of mitochondrial respiratory chain supramolecular complex: NADH-cytosome coxidoreductase, NCR in the peripheral blood leucocyte namely mitochondrial NCR enzymatic activity level is closely related with the organ dysfunction and prognosis of sepsis. The invention also provides a detection method and detection reagent for detecting the peripheral blood leucocyte mitochondrial respiratory chain supramolecular complex NCR enzymatic activity. The provided method can rapidly, specifically, and sensitively measure the mitochondrial NCR enzymatic activity of a sample, and has an important meaning on the sepsis diagnosis, severity degree monitoring, and prognosis evaluation.

The present invention refers to thymoquinone, a main constituent of the volatile oil of Nigella sativa, and its protective effect against sepsis syndrome morbidity, mortality and associated organ dysfunctions. In particular, the present invention refers to thymoquinone for use in the prevention and / or treatment of sepsis syndrome. The present invention further refers to a pharmaceutical composition and a kit.

The present invention provides an agent for the prophylaxis or treatment of severe sepsis, which contains a compound represented by the formula (I):or, the formula (II):or a salt thereof or a prodrug thereof, a TLR signal inhibitor containing a non-peptide compound and an agent for the prophylaxis or treatment of organ dysfunction and the like, which contains a TLR signal inhibitory substance.

A method for implanting an electrode to an endopelvic portion of a pelvic nerve includes the steps of: laparoscopically forming a first entry through the abdomen; introducing an applicator assembly through a second entry, the applicator assembly comprising a flexible introducer sleeve and a curved applicator tool disposed in the sleeve; manipulating a proximal end of the curved applicator tool to position a distal end of the curved applicator tool at an identified exposed nerve; and placing an electrode lead through the applicator assembly to the nerve.

The present invention relates to the field of organ transplantation. More specifically, the present invention provides methods for predicting organ function after transplantation. In certain embodiments, the method comprises measuring mitochondrial membrane potential from a biopsy sample from the donor organ. The present invention is also applicable to organ dysfunction in general. More specifically, the methods of the present invention may be useful in formulating prognoses for patients with acute or chronic organ dysfunction due to ischemia, infection, drug injury or age. In this rapid procedure, only small samples of tissue are required, enabling the clinical application of mitochondrial function previously thought impractical.

The present invention relates to use an agent for the prevention and / or treatment of multiple organ dysfunction syndrome (MODS) or multiple organ failure (MOF) comprising interleukin-22 (IL-22) as an effective ingredient. The present invention is applicable to prevention of or therapy for diseases from sepsis, septic shock, liver failure, to multiple organ dysfunction syndromes. More particularly, the present invention is useful for an emergency medical service, for treatment of injury caused by a traffic accident, burns, heat attacks, hypercytokinemia or severe infective diseases.

The present invention relates to use an agent for the prevention and / or treatment of multiple organ dysfunction syndrome (MODS) or multiple organ failure (MOF) comprising interleukin-22 (IL-22) as an effective ingredient. The present invention is applicable to prevention of or therapy for diseases from sepsis, septic shock, liver failure, to multiple organ dysfunction syndromes. More particularly, the present invention is useful for an emergency medical service, for treatment of injury caused by a traffic accident, burns, heat attacks, hypercytokinemia or severe infective diseases.

The invention relates to the treatment and diagnosis of organ dysfunction caused by ischemia reperfusion injury. In particular, the invention relates to sphinganine-1-phosphate, a sphingolipid metabolite, and its use in the diagnosing, preventing, and / or treating ischemia reperfusion-associated disorders, including, without limitation, disorders of the kidney, liver, lung, brain, and heart.

The invention provides a construction method of an acute pancreatitis animal model. According to the construction method, high-fat feed and alcohol are used for jointly inducing animals to form acute pancreatitis. Obesity caused by high-fat feed and alcohol can synergistically cause pathological damage to pancreas of mice, local inflammatory response of pancreas and inflammatory response of lungs and the whole body. In a basic obesity state, the morbidity condition of a large amount of alcohol drinking of the animal model is closer to human morbidity, pancreatic injury is obvious and accompanied by multiple organ dysfunction syndromes, and the animal model accords with the clinical characteristic that obese acute pancreatitis patients are prone to severe illness. The animal model is simple in modeling method, good in repeatability and high in clinical correlation, the model can be used for studying the pathogenesis of obesity and alcohol-related acute pancreatitis, and an important basis is provided for screening treatment targets and studying medical transformation.

The present invention refers to thymoquinone, a main constituent of the volatile oil of Nigella sativa, and its protective effect against sepsis syndrome morbidity, mortality and associated organ dysfunctions. In particular, the present invention refers to thymoquinone for use in the prevention and / or treatment of sepsis syndrome. The present invention further refers to a pharmaceutical composition and a kit.

A system and method is disclosed for measuring muscle reflexes (e.g., a bulbocavernosus reflex) as a tool for identifying / diagnosing dysfunctions (e.g., spinal cord abnormalities, bladder voiding dysfunction, and sexual organ dysfunction) non-invasively by using mechanical stimulation. The system and method includes a probe having a predetermined patient contacting portion, wherein when the contacting portion is moved into contact with a particular area of the patient (e.g., the patient's genitals), the contact induces a muscle reflex. The probe detects the pressure resulting from the contacting portion being abruptly and forcibly brought into contact with the particular area. Such detection is used to electronically initiate capture of electrical responses from a plurality of electrodes placed on the patient's skin in proximity to the particular area. Such electrical responses are processed to determine characteristics of the patient's reflexes of one or more muscles adjacent to the electrodes.